JNK1alpha1/SAPK1c, active

N-terminal 6His-tagged recombinant, human full length JNK1α1/SAPK1c.

Catalog #: 14-327

$399.00$2,989.00


Inquire
Biological Information
Background Information:
c-Jun N-terminal kinases (JNKs), a stress-activated protein kinase (SAPK), is involved in cellular responses to environmental stresses. JNK kinases can be activated by stimuli such as UV light, radiation, protein synthesis inhibitors, ceramide, DNA-damaging drugs, chemopreventive drugs, TNF-a, and interleukin 1. JNK binds to an NH2-terminal region of ATF2 and c-Jun and phosphorylates two sites within the activation domain of each transcription factor. Three JNK genes (Jnk1, -2 and -3) have been identified in humans; however, splice variants result in a total of 10 isoforms. Therapeutic inhibition of JNK may provide clinical benefit in disease as diverse as immune inflammatory (joint, bowel, pulmonary), ischemic injury (brain, cardiac) and neurodegenerative (Alzheimer's, Parkinson's) diseases. EMBL L26318
Target Class:
Kinase
Family:
Ser/Thr Kinase; MAPK; JNK subfamily
Accession Number:
NM_002750.2; NM_139046.1; NM_139047.1; NM_139049.1
Target Name:
JNK1α1/SAPK1c
Target Aliases:
MAPK8, JNK1, JNK21B1/2, PRKM8, JNK-46, JNK, SAPK1, JNK1A2
Target Species:
Human
Usage
Product Type:
Enzymes
Application:
Drug Discovery & Development
Storage Conditions:
1 year at -70°C
Usage Disclaimer:
These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information.

Datasheets

14-327x Datasheet

View Document